Enhancer RNAs (eRNAs) are a class of non-coding RNA, which play a critical role in tumor progression.1 Previous studies have indicated abundant CpG methylation, somatic mutation, and copy number variation in eRNA regions in cancers.2,3 We constructed a landscape of genetic alteration-driven eRNAs and provided an integrative pipeline to identify drug candidates that affect eRNA activity. Furthermore, we explored the prognostic value of genetic alteration-driven eRNAs.